Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial Meeting Abstract
| Authors: | Costa, L.; Popat, R.; Siegel, D.; Schjesvold, F.; Usmani, S.; Bahlis, N. J.; Oriol, A.; Chu, M.; Ali, S. A.; Ramasamy, K.; Hartley-Brown, M.; Martínez-Lopez, J.; Gaudy, A.; Kurtova, A.; Zhang, W.; Sarmiento, R.; Dietrich, A.; Katz, J.; Pourdehnad, M.; Richardson, P. |
| Abstract Title: | Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S19 |
| Language: | English |
| ACCESSION: | WOS:001325737900030 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01870-6 |
| Notes: | Meeting Abstract: OA-29 -- Source: Wos |
